摘要
目的 比较新疆地区维吾尔族、汉族中晚期宫颈癌患者的疗效并分析影响预后的因素.方法 回顾分析204例中晚期宫颈癌患者资料,其中维吾尔族124例,汉族80例.单纯放疗100例,同期放化疗49例,55例术前后装治疗.Kaplan-Meier法计算总生存率,Logrank法检验和单因素预后分析,Cox法多因素预后分析.结果 随访率为97.5％,随访满5年者为102例.汉族和维吾尔族患者1、3、5年总生存率分别为81.2％、66.3％、51.4％和83.4％、62.8％、49.2％(x2=3.21,P=0.273).单因素分析显示产次、地区分布、病理类型、临床分期、淋巴结转移、放疗方法对总生存有影响(x2 =2.35、11.34、7.12、6.73、4.79、13.60,P=0.049、0.029、0.031、0.037、0.041、0.021).多因素分析显示产次、病理类型、淋巴结转移、临床分期、放疗方法对总生存有影响(x2 =8.36、24.94、10.69、5.63、9.50,P=0.002、0.001、0.021、0.018、0.031).结论 维吾尔族和汉族中晚期宫颈癌患者预后相似,产次≥3次、腺癌、淋巴结转移、临床分期越晚以及单纯放疗预后差.
Abstract
Objective To compare the treatment outcome and prognostic factors in patients with advanced cervical cervical cancer between Han and Uygur in Xinjiang district.Methods 204 patients with advanced cervical cancer were retrospectively analyzed.Eighty patients were Han 80 and 124 were Uyghur.100 patients received radiotherapy alone and 49 with concurrent radiochemotherapy,and 55 had brachytherapy followed by surgery.The survival rate was calculated by Kaplan-Meier method and the difference was compared by Logrank test.Multivariate analysis was performed using Cox regression model.Results The follow-up rate was 97.5％.The number of patients with at least 5 years of follow up was 102.The 1-,3-and 5-year overall survival rates in Han and Uygur patients were 81.2％,66.3％,51.4％ and 83.4％,62.8％,49.2％,respectively (x2 =3.21,P =0.273).Univariate analysis showed that parity,geographical distribution,pathological type,clinical stage,lymph node involvement and treatment were prognostic factors for overall survival (x2 =2.35,11.34,7.12,6.73,4.79,13.60,P=0.049,0.029,0.031,0.037,0.041,0.021).Multivariate analysis showed that parity,geographical distribution,pathological type,clinical stage,lymph node involvement and treatment were independent prognostic factors for overall survival (x2 =8.36,24.94,10.69,5.63,9.50,P =0.002,0.001,0.021,0.018,0.031).Conclusions There is no significant difference in overall survival rate of patients with advanced cervical cancer between Han and Uighur.Patients with parity more than or equal to 3 times,advanced clinical stage or adenocarcinoma have poor prognoses.
NETL
NSTL
维普
万方数据